Internal Medicine, Hematology · Charlotte, NC
NPI
1356495949
Since 2007
Specialty
Internal Medicine, Hematology
Code 207RH0000X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1021 Morehead Medical Dr, Ste A
Charlotte, NC, 28204
Phone (980) 442-2000
Groups this clinician bills Medicare through
Medicare paid, 2024
$18K
244 services
Medicare patients, 2024
70
Average age 74
Drug cost, 2024
$3.7M
751 prescriptions
Company payments, 2025
$64K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael R Grunwald was code 99214 (office e&m - established), 90 times for 45 patients. In total Michael R Grunwald billed 244 services in 12 codes, and Medicare paid $18K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-07-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 90 | 45 | $62.41 | $5,617 |
| 99215 Office E&M - Established | Facility | 87 | 29 | $103.14 | $8,973 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 25 | 11 | $22.84 | $571 |
By year: 2022 $18K for 212 services; 2023 $15K for 187 services; 2024 $18K for 244 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael R Grunwald prescribed most often to Medicare patients was Jakafi (Ruxolitinib Phosphate), with 122 prescriptions and refills. In total Michael R Grunwald wrote 751 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Jakafi Ruxolitinib Phosphate | 122 | 130 | 11 | $2.0M |
| Acyclovir Generic | 79 | 175 | 20 | $1,487 |
| Hydroxyurea Generic | 34 | 101 | 11 | $420 |
| Posaconazole Generic | 28 | 28 | Under 11 | $36K |
| Venclexta Venetoclax | 28 | 28 | Under 11 | $79K |
| Pegasys Peginterferon Alfa-2a | 23 | 23 | Under 11 | $79K |
| Vonjo Pacritinib Citrate | 22 | 22 | Under 11 | $559K |
| Potassium Chloride Generic | 21 | 57 | Under 11 | $798 |
| Levofloxacin Generic | 19 | 39 | Under 11 | $324 |
| Diphenhydramine Hcl Generic | 18 | 18 | Under 11 | $4,321 |
| Potassium Chloride-0.9% Nacl Potassium Chloride In 0.9%nacl | 17 | 17 | Under 11 | $399 |
| Onureg Azacitidine | 16 | 16 | Under 11 | $233K |
| Cresemba Isavuconazonium Sulfate | 16 | 16 | Under 11 | $96K |
| Montelukast Sodium Generic | 15 | 43 | Under 11 | $210 |
| Imatinib Mesylate Generic | 15 | 15 | Under 11 | $16K |
Brand drugs: 333 claims; generic drugs: 418 claims; opioid claims: 16.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael R Grunwald $64K ($64K in general payments such as food, travel and fees) from 12 companies. The largest payer was Incyte Corporation with $28K.
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation INCY | 42 | $28K |
| Sobi, Inc SOBI.ST | 6 | $12K |
| Geron Corporation GERN | 12 | $7,612 |
| Shorla Oncology Inc. | 1 | $4,950 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $4,208 |
| Autolus Inc | 4 | $3,820 |
| Sanofi US Services Inc. SNY | 2 | $2,315 |
| Daiichi Sankyo Inc. 4568.T | 1 | $650 |
| Amgen Inc. AMGN | 1 | $366 |
| National Marrow Donor Program | 2 | $325 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.